
    
      The primary endpoint is to determine the maximum tolerated dose of Iodine-131 Anti B-1
      Antibody in patients with previously treated NHL having more than 25% bone marrow involvement
      with lymphoma. Secondary endpoints include assessment of response rate, duration of response,
      relapse-free survival, time to treatment failure, safety, and survival.

      The dose escalation will be started at 45cGy and will be escalated in 10cGy increments until
      the maximum tolerated dose in reached.
    
  